Cinacalcet may suppress kidney enlargement in hemodialysis patients with autosomal dominant polycystic kidney disease
Abstract A massively enlarged kidney can impact quality of life of autosomal dominant polycystic kidney disease (ADPKD) patients. A recent in vitro study demonstrated that an allosteric modulator of the calcium sensing receptor decreases adenosine-3′,5′-cyclic monophosphate, an important factor for...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/4d7d233e64e54f819c340bec880d0e73 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:4d7d233e64e54f819c340bec880d0e73 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:4d7d233e64e54f819c340bec880d0e732021-12-02T16:58:20ZCinacalcet may suppress kidney enlargement in hemodialysis patients with autosomal dominant polycystic kidney disease10.1038/s41598-021-89480-12045-2322https://doaj.org/article/4d7d233e64e54f819c340bec880d0e732021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-89480-1https://doaj.org/toc/2045-2322Abstract A massively enlarged kidney can impact quality of life of autosomal dominant polycystic kidney disease (ADPKD) patients. A recent in vitro study demonstrated that an allosteric modulator of the calcium sensing receptor decreases adenosine-3′,5′-cyclic monophosphate, an important factor for kidney enlargement in ADPKD. Therefore, the present study was performed to determine whether cinacalcet, a calcium sensing receptor agonist, suppresses kidney enlargement in hemodialysis patients with ADPKD. Alteration of total kidney volume together with clinical parameters was retrospectively examined in 12 hemodialysis patients with ADPKD treated at a single institution in Japan. In the non-cinacalcet group with longer hemodialysis duration (n = 5), total kidney volume had an annual increase of 4.19 ± 1.71% during an overall period of 877 ± 494 days. In contrast, the annual rate of increase in total kidney volume in the cinacalcet group (n = 7) was significantly suppressed after cinacalcet treatment, from 3.26 ± 2.87% during a period of 734 ± 352 days before the start of cinacalcet to − 4.71 ± 6.42% during 918 ± 524 days after initiation of treatment (p = 0.047). The present findings showed that cinacalcet could be a novel therapeutic tool for suppression of kidney enlargement in hemodialysis patients with ADPKD.Shinya NakataniKozo NishideSenji OkunoEiji IshimuraDaijiro KabataFumiyuki MoriokaYuri MachibaHideki UedonoAkihiro TsudaShigeichi ShojiMasaaki InabaKatsuhito MoriTomoyuki YamakawaMasanori EmotoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Shinya Nakatani Kozo Nishide Senji Okuno Eiji Ishimura Daijiro Kabata Fumiyuki Morioka Yuri Machiba Hideki Uedono Akihiro Tsuda Shigeichi Shoji Masaaki Inaba Katsuhito Mori Tomoyuki Yamakawa Masanori Emoto Cinacalcet may suppress kidney enlargement in hemodialysis patients with autosomal dominant polycystic kidney disease |
| description |
Abstract A massively enlarged kidney can impact quality of life of autosomal dominant polycystic kidney disease (ADPKD) patients. A recent in vitro study demonstrated that an allosteric modulator of the calcium sensing receptor decreases adenosine-3′,5′-cyclic monophosphate, an important factor for kidney enlargement in ADPKD. Therefore, the present study was performed to determine whether cinacalcet, a calcium sensing receptor agonist, suppresses kidney enlargement in hemodialysis patients with ADPKD. Alteration of total kidney volume together with clinical parameters was retrospectively examined in 12 hemodialysis patients with ADPKD treated at a single institution in Japan. In the non-cinacalcet group with longer hemodialysis duration (n = 5), total kidney volume had an annual increase of 4.19 ± 1.71% during an overall period of 877 ± 494 days. In contrast, the annual rate of increase in total kidney volume in the cinacalcet group (n = 7) was significantly suppressed after cinacalcet treatment, from 3.26 ± 2.87% during a period of 734 ± 352 days before the start of cinacalcet to − 4.71 ± 6.42% during 918 ± 524 days after initiation of treatment (p = 0.047). The present findings showed that cinacalcet could be a novel therapeutic tool for suppression of kidney enlargement in hemodialysis patients with ADPKD. |
| format |
article |
| author |
Shinya Nakatani Kozo Nishide Senji Okuno Eiji Ishimura Daijiro Kabata Fumiyuki Morioka Yuri Machiba Hideki Uedono Akihiro Tsuda Shigeichi Shoji Masaaki Inaba Katsuhito Mori Tomoyuki Yamakawa Masanori Emoto |
| author_facet |
Shinya Nakatani Kozo Nishide Senji Okuno Eiji Ishimura Daijiro Kabata Fumiyuki Morioka Yuri Machiba Hideki Uedono Akihiro Tsuda Shigeichi Shoji Masaaki Inaba Katsuhito Mori Tomoyuki Yamakawa Masanori Emoto |
| author_sort |
Shinya Nakatani |
| title |
Cinacalcet may suppress kidney enlargement in hemodialysis patients with autosomal dominant polycystic kidney disease |
| title_short |
Cinacalcet may suppress kidney enlargement in hemodialysis patients with autosomal dominant polycystic kidney disease |
| title_full |
Cinacalcet may suppress kidney enlargement in hemodialysis patients with autosomal dominant polycystic kidney disease |
| title_fullStr |
Cinacalcet may suppress kidney enlargement in hemodialysis patients with autosomal dominant polycystic kidney disease |
| title_full_unstemmed |
Cinacalcet may suppress kidney enlargement in hemodialysis patients with autosomal dominant polycystic kidney disease |
| title_sort |
cinacalcet may suppress kidney enlargement in hemodialysis patients with autosomal dominant polycystic kidney disease |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/4d7d233e64e54f819c340bec880d0e73 |
| work_keys_str_mv |
AT shinyanakatani cinacalcetmaysuppresskidneyenlargementinhemodialysispatientswithautosomaldominantpolycystickidneydisease AT kozonishide cinacalcetmaysuppresskidneyenlargementinhemodialysispatientswithautosomaldominantpolycystickidneydisease AT senjiokuno cinacalcetmaysuppresskidneyenlargementinhemodialysispatientswithautosomaldominantpolycystickidneydisease AT eijiishimura cinacalcetmaysuppresskidneyenlargementinhemodialysispatientswithautosomaldominantpolycystickidneydisease AT daijirokabata cinacalcetmaysuppresskidneyenlargementinhemodialysispatientswithautosomaldominantpolycystickidneydisease AT fumiyukimorioka cinacalcetmaysuppresskidneyenlargementinhemodialysispatientswithautosomaldominantpolycystickidneydisease AT yurimachiba cinacalcetmaysuppresskidneyenlargementinhemodialysispatientswithautosomaldominantpolycystickidneydisease AT hidekiuedono cinacalcetmaysuppresskidneyenlargementinhemodialysispatientswithautosomaldominantpolycystickidneydisease AT akihirotsuda cinacalcetmaysuppresskidneyenlargementinhemodialysispatientswithautosomaldominantpolycystickidneydisease AT shigeichishoji cinacalcetmaysuppresskidneyenlargementinhemodialysispatientswithautosomaldominantpolycystickidneydisease AT masaakiinaba cinacalcetmaysuppresskidneyenlargementinhemodialysispatientswithautosomaldominantpolycystickidneydisease AT katsuhitomori cinacalcetmaysuppresskidneyenlargementinhemodialysispatientswithautosomaldominantpolycystickidneydisease AT tomoyukiyamakawa cinacalcetmaysuppresskidneyenlargementinhemodialysispatientswithautosomaldominantpolycystickidneydisease AT masanoriemoto cinacalcetmaysuppresskidneyenlargementinhemodialysispatientswithautosomaldominantpolycystickidneydisease |
| _version_ |
1718382325277917184 |